We develop and commercialize clinical-stage oncology and rare disease programs that originate in pharmaceutical or biotechnology companies and which are not prioritised for further development for strategic portfolio reasons.
With the streamlined efficiency of a small company and the combination of our internal expertise and external resources, we are able to rapidly progress these programs into late-stage development and, subsequently, to either in-house commercialization or through to strategic partnership for launch and sales.
With deep clinical experience in oncology and rare disease therapies, from Phase 1 through to approval and launch, Mereo is able to offer a comprehensive, seamless and scalable development capability, facilitating rapid transfer and start-up of clinical programs from pharmaceutical and biotech partners.
We work collaboratively with all stakeholders, including regulators, healthcare authorities, pricing & reimbursement decision-makers, treating physicians and patient community representatives to find the optimum pathways to efficiently bring life-changing therapies to patients who may have no other treatment options.
We seek to maximize the value of our specialty product portfolio through commercial partnerships. These include:
- Acumapimod (BCT-197)
Acute Exacerbations of COPD (AECOPD)
- Leflutrozole (BGS-649)
Male Infertility assocaited with Hypogonadotropic Hypogonadism ("HH")